IBD: 心理承受能力与IBD患者的更少疾病活动,更好的生活质量以及更少的炎症性肠病手术相关

2021-05-21 MedSci原创 MedSci原创

炎症性肠病(IBD)包括溃疡性结肠炎(UC)和克罗恩病(CD)两种疾病,在美国影响超过了100万人口,在欧洲影响250万了人口。

       炎症性肠病(IBD)包括溃疡性结肠炎(UC)和克罗恩病(CD)两种疾病,在美国影响超过了100万人口,在欧洲影响250万了人口。这些疾病有可能极大地影响一个人的生活历程和个人选择,而较高的心理适应能力可以促进IBD的良好预后。但是一旦心理承受能力不佳则造成了巨大的心理负担,可能会导致肠损伤,疲劳和残疾,从而给患者带来持续的压力。一个人从逆境中恢复的能力是否会影响疾病进程尚不清楚。这项研究的目的是探究韧性和IBD疾病活动性,生活质量(QoL)和IBD相关手术之间的关系。

 

       研究人员在一个医疗中心招募了符合条件的IBD患者,所有患者均按要求填写了Connor-Davidson弹性量表问卷,该问卷用于测量心理承受能力(高弹性评分≥35)。主要结局是IBD疾病活动度,通过Mayo评分和Harvey-Bradshaw指数(HBI)分别对UC和CD进行评估,同时研究人员还评估了QoL和IBD相关的手术情况。进行了多元线性回归,以评估高适应力与疾病活动性和生活质量的关系。

 

      本项研究共包括了92例溃疡性结肠炎(UC)和137例克罗恩病(CD)患者。在27%的UC患者和21.5%的CD患者中发现患者的心理承受能力较高。在UC患者中,高弹性心理承受能力的患者的平均Mayo得分为1.54,低弹性患者的平均Mayo得分为4.31,P <0.001。在CD患者中,高弹性患者的平均HBI为2.31,低弹性患者的平均HBI为3.95,P = 0.035。在多变量分析中,高心理承受能力与UC(P <0.001)和CD(P = 0.037)的QoL改善有关。同时高心理承受能力还与CD患者中较少的手术相关(P = 0.001)。

 

       本项研究证实高心理承受能力与IBD患者疾病活动度降低和QoL改善以及CD患者手术次数减少独立相关。

 

 

原始出处:

Priya Sehgal. Et al. High Levels of Psychological Resilience Associated With Less Disease Activity, Better Quality of Life, and Fewer Surgeries in Inflammatory Bowel Disease. Inflammatory Bowel Diseases.2021.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1756113, encodeId=583e1e56113c9, content=<a href='/topic/show?id=78e1e06924a' target=_blank style='color:#2F92EE;'>#疾病活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70692, encryptionId=78e1e06924a, topicName=疾病活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57fa37069463, createdName=xue8614, createdTime=Sun Mar 20 07:46:50 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263654, encodeId=b19d1263654c4, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sun May 23 06:46:50 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547438, encodeId=d230154e4388b, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Sun May 23 06:46:50 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967494, encodeId=c79896e4941f, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5445497016, createdName=Yanduidui, createdTime=Fri May 21 15:52:28 CST 2021, time=2021-05-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1756113, encodeId=583e1e56113c9, content=<a href='/topic/show?id=78e1e06924a' target=_blank style='color:#2F92EE;'>#疾病活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70692, encryptionId=78e1e06924a, topicName=疾病活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57fa37069463, createdName=xue8614, createdTime=Sun Mar 20 07:46:50 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263654, encodeId=b19d1263654c4, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sun May 23 06:46:50 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547438, encodeId=d230154e4388b, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Sun May 23 06:46:50 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967494, encodeId=c79896e4941f, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5445497016, createdName=Yanduidui, createdTime=Fri May 21 15:52:28 CST 2021, time=2021-05-21, status=1, ipAttribution=)]
    2021-05-23 bnurmamat
  3. [GetPortalCommentsPageByObjectIdResponse(id=1756113, encodeId=583e1e56113c9, content=<a href='/topic/show?id=78e1e06924a' target=_blank style='color:#2F92EE;'>#疾病活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70692, encryptionId=78e1e06924a, topicName=疾病活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57fa37069463, createdName=xue8614, createdTime=Sun Mar 20 07:46:50 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263654, encodeId=b19d1263654c4, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sun May 23 06:46:50 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547438, encodeId=d230154e4388b, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Sun May 23 06:46:50 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967494, encodeId=c79896e4941f, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5445497016, createdName=Yanduidui, createdTime=Fri May 21 15:52:28 CST 2021, time=2021-05-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1756113, encodeId=583e1e56113c9, content=<a href='/topic/show?id=78e1e06924a' target=_blank style='color:#2F92EE;'>#疾病活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70692, encryptionId=78e1e06924a, topicName=疾病活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57fa37069463, createdName=xue8614, createdTime=Sun Mar 20 07:46:50 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263654, encodeId=b19d1263654c4, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sun May 23 06:46:50 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547438, encodeId=d230154e4388b, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Sun May 23 06:46:50 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967494, encodeId=c79896e4941f, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5445497016, createdName=Yanduidui, createdTime=Fri May 21 15:52:28 CST 2021, time=2021-05-21, status=1, ipAttribution=)]
    2021-05-21 Yanduidui

    0

相关资讯

IBD: 粪钙卫蛋白水平可预测IBD患者肠道组织学缓解和内镜缓解率

在过去的十年中,粘膜愈合成为了炎症性肠病(IBD)患者的治疗目标。达到MH的患者会有更好的长期预后,如复发风险降低,无类固醇缓解期延长,较少住院几率等。

IBD: 炎性肠病患者门静脉血栓形成的发生风险分析

门静脉血栓形成(PVT)是炎症性肠病(IBD)的常见并发症,预后不佳。本项研究旨在试图更好地描述IBD患者出现PVT的危险因素,并比较不同的治疗方法及对于IBD相关PVT的预后。

JCC: 存在肺功能受累的活动性IBD患者对生物治疗的反应差异

在溃疡性结肠炎(UC)患者的流行病学研究中,研究人员观察到因呼吸道疾病死亡率有增加的现象,这是潜在的被严重低估的炎症性肠病(IBD)肠外表现的影响。

JCC:饮食摄入模式与IBD患者发生疾病复发风险有关

目前已经有研究表明,饮食与炎症性肠病(IBD)的发作有关。多达一半的IBD患者认为饮食会导致疾病复发。

GUT: 英夫利昔单抗治疗的IBD患者的抗新冠病毒的抗体反应会被减弱

新冠病毒(SARS-CoV-2)感染和/或接种疫苗后诱导保护性免疫对于抑制传播至关重要。

AP&T: 血清甲状腺素T3与甲状腺素T4(T3 / T4)的比值可预测老年IBD患者对生物疗法的治疗效果

老年炎症性肠病(IBDs)的发病率正在逐渐增加,并且老年对于目前的药物治疗方案有着与年轻人不一样的反应,因此,需要另外的生物标记物来优化其治疗方法。